The ACTS Trial: N-acetylcysteine (NAC) and Night-splinting as a Non-operative Treatment for Carpal Tunnel Syndrome

PHASE4RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

April 1, 2022

Primary Completion Date

April 1, 2026

Study Completion Date

October 1, 2026

Conditions
Carpal Tunnel SyndromeHand Injuries and DisordersNerve CompressionSplintsCarpal TunnelCarpal Tunnel Release
Interventions
DRUG

N-Acetyl cysteine

In addition to splinting, both groups will receive an oral tablet to take daily for 8 weeks. Participants assigned to the experimental group will receive oral NAC (500 mg PO daily for eight weeks; based on recommended daily dose for use as an antioxidant and dosing in previous human clinical trials and animal studies), and those assigned to the control group will be given a similar looking placebo with identical instructions. Tablets will be provided in a blister pack to assist with compliance.

DEVICE

Wrist Splint

Participants in both arms will be given a standard prescription for a prefabricated night splint which keeps the wrist in a neutral position and instructed on proper use and the importance of consistent use. To limit splint variability, we will ensure that splint prescriptions are written such that a MedSpec Wrist Lacer II splint is obtained from the patient's pharmacy. This is the most commonly available brand locally and meets the criteria for wrist, metacarpophalangeal, and interphalangeal joint positioning. They will be advised to wear the splint consistently during sleeping hours on their affected wrist for eight weeks, as is the standard of practice.

Trial Locations (1)

B3H3A6

RECRUITING

Queen Elizabeth II Health Sciences Center, Halifax Infirmary Site, Halifax

All Listed Sponsors
lead

Emily Krauss

OTHER